CapsoVision, Inc. Common Stock (CV) is a publicly traded Healthcare sector company. As of May 21, 2026, CV trades at $6.48 with a market cap of $317.77M and a P/E ratio of -2.78. CV moved -0.91% today. Year to date, CV is -23.67%; over the trailing twelve months it is flat. Its 52-week range spans $3.43 to $15.37. Analyst consensus is buy with an average price target of $10.50. Rallies surfaces CV's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
CapsoVision Q1 Revenue Flat at $2.8M; AI Feature FDA Clearance Expected: CapsoVision’s first-quarter revenue held at $2.8 million while gross profit dropped 11% to $1.3 million as operating expenses rose $1.5 million. The company raised $14 million in equity financing and expects FDA clearance of its AI-assisted CapsoCam Plus reading feature mid-year, serving 167,000 patients.
| Metric | Value |
|---|---|
| Price | $6.48 |
| Market Cap | $317.77M |
| P/E Ratio | -2.78 |
| EPS | $-2.32 |
| Dividend Yield | 0.23% |
| 52-Week High | $15.37 |
| 52-Week Low | $3.43 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $13.56M |
| Net Income | $-26.97M |
| Gross Margin | 51.67% |
2 analysts cover CV: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $10.50.